TWD
LXRX icon

True Wealth Design’s Lexicon Pharmaceuticals LXRX Stock Holding History

True Wealth Design’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2
Closed -$4 – 2787
2026
Q1 		$4 Sell
2
-47
-96% -$68 ﹤0.01% 2694
2025
Q4 		$57 Sell
49
-36
-42% -$49 ﹤0.01% 2406
2025
Q3 		$115 Sell
85
-658
-89% -$747 ﹤0.01% 2423
2025
Q2 		$703 Buy
743
+124
+20% +$80 ﹤0.01% 1604
2025
Q1 		$286 Buy
+619
New +$391 ﹤0.01% 1798

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

True Wealth Design's LXRX Position: Q2 2026 in Review

True Wealth Design sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2026, closing a stake of 2 shares — an estimated $4 sold.

True Wealth Design first reported a position in LXRX in Q1 2025 and held it in 5 quarters. The position peaked at $703 in Q2 2025. 149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • True Wealth Design reported no remaining Lexicon Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • True Wealth Design sold 2 Lexicon Pharmaceuticals shares in Q2 2026, an estimated $4.
  • True Wealth Design first reported a position in Lexicon Pharmaceuticals in Q1 2025 and held it in 5 quarters.
  • True Wealth Design's Lexicon Pharmaceuticals position peaked at $703 in Q2 2025.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.